We are live on ! Find out more
RGNX icon

Regenxbio

186 hedge funds and large institutions have $1.51B invested in Regenxbio in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 69 increasing their positions, 60 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 60

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.46% less ownership

Funds ownership: 82.86% → 80.4% (-2.5%)

11% less call options, than puts

Call options by funds: $11.3M | Put options by funds: $12.7M

11% less capital inflows, than outflows

Capital inflows: $172M | Capital outflows: $193M

12% less funds holding

Funds holding: 211 → 186 (-25)

53% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 43

Holders
186
Holders Change
-25
Holders Change %
-11.85%
% of All Funds
4.02%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
69
Reduced
60
Closed
43
Calls
$11.3​M
Puts
$12.7​M
Net Calls
-⁠$1.39​M
Net Calls Change
+$11.1​M

RGNX Hedge Fund Activity: Q2 2019 in Review

186 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2019, worth a combined $1.51B — down 13% from $1.73B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of RGNX and 20 opened new positions — a net loss of 23 holders — while 60 trimmed existing stakes and 69 added.

The largest buyer was Carmignac Gestion, adding an estimated $37.1M. The largest seller was Renaissance Technologies, cutting an estimated $25.9M.

  • 186 institutional investors held Regenxbio (RGNX) as of Q2 2019, down from 211 in Q1 2019.
  • Funds reported $1.51B of Regenxbio stock for Q2 2019, down 13% quarter-over-quarter.
  • 20 funds opened new Regenxbio positions in Q2 2019 and 43 closed out, a net change of -23 holders.
  • The largest Regenxbio buyer in Q2 2019 was Carmignac Gestion, an estimated $37.1M added.
  • The largest Regenxbio seller in Q2 2019 was Renaissance Technologies, an estimated $25.9M sold.

Based on aggregated 13F filings for Q2 2019.